#### University of Massachusetts Medical School

#### eScholarship@UMMS

PEER Liberia Project

UMass Medical School Collaborations in Liberia

2020-04-17

#### **Focused Review of Antiretroviral Treatment**

Morgan Younkin
Lawrence Family Medicine Residency

#### Let us know how access to this document benefits you.

Follow this and additional works at: https://escholarship.umassmed.edu/liberia\_peer

Part of the Family Medicine Commons, Health Services Administration Commons, Infectious Disease Commons, Medical Education Commons, Virus Diseases Commons, and the Viruses Commons

#### **Repository Citation**

Younkin M. (2020). Focused Review of Antiretroviral Treatment. PEER Liberia Project. https://doi.org/10.13028/q57k-mm25. Retrieved from https://escholarship.umassmed.edu/liberia\_peer/72

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in PEER Liberia Project by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.

## Session 1 & 2 Review

## ART Regimen: Building Blocks

#### 3 meds

- 2 fully active
- PI needs a ritonavir "booster"

Inhibits CYP 450-3A4



concentration of PI

Core Backbone

INSTI + NRTI + NRT

PI + NRTI + NRTI

NNRTI + NRTI + NRTI

## Nucleoside Reverse Transcriptase Inhibitor NRTI

#### Tenofovir [TDF]

- Need for HIV-HBV co-infxn [alternative = entecavir]
- Dose reduction for CrCl <50</li>

#### Lamivudine [3TC]

- Well, tolerated
- in all 1st & 2nd line regimens

#### Abacavir [ABC]


Hypersensitivity reaction = absolute contraindication


#### Zidovudine [AZT]

- Q12hr dosing
- NOT if hgb <8</li>
- Watch for anemia

#### **Available Combo Pills**

- ABC/3TC
- TDF/3TC
- AZT/3TC





# Non-Nucleoside Reverse Transcriptase Inhibitor NNRTI

#### Nevirapine [NVP]

- 1st line, but not for ART start
- SE: hypersensitivity reaction, rash, hepatitis

#### Efavirenz [EFV]

- 1st line, but not for ART start
- SE: neuropsych, insomnia, nightmares, dizziness, gynecomastia

#### Available Single Tablet Regimen

- AZT / 3TC / NVP
- TDF / 3TC / EFV "**B+**"
  - Very similar to "Atripla"

Core


NNRTI

+

Backbone

NRTI +

+ NRT



# Protease Inhibitor PI

Lopinavir / ritonavir [LPV/r – Kaletra]

- 2<sup>nd</sup> line
- diarrhea


Atazanavir / ritonavir [ATV/r]

- 2<sup>nd</sup> line
- Do NOT use with rifampicin for MTB tx
- Benign hyperbili/jaundice

Darunavir / ritonavir [DRV + r]

- 3<sup>rd</sup> line
- Must take separately

Not Available in Single Tablet Regimen



## Integrase Strand Transfer Inhibitor INSTI

#### Dolutegravir [DTG]

- 1st line for patients 30kg + without childbearing potential
- WHO: 1st line treatment for pregnant women
- SE mild: HA, insomnia, nausea
  - Check LFTs before/after initiation if known liver disease
- BID with rifapentine for MTB treatment

Available Single Tablet Regimen

TDF / 3TC / DTG

Core


INSTI

Backbone

.

NRTI

+ NR



## ART key

DTG

dolutegravir

ATV/r

atazanvir / ritonavir

LPV/r

lopinavir / ritonavir

DRV + r

darunavir / ritonavir

NVP

nevirapine

**EFV** 

efavirenz

TDF

tenofovir

ABC

abacavir


3TC

lamivudine

AZT

zidovudine

## First Line ART



### **START**

Core

Backbone

Men 30kg Women 45yo +

DTG

/

TDF

/

3TC

Women of "B+" childbearing potential

EFV

/

TDF

′ 3TC

Patients < 30kg

NVP

/


AZT

3

**Not for START** 

Core Backbone

## 2<sup>nd</sup> line ART



### Not for START\*

Core Backbone
$$ATV/r + \begin{bmatrix}
TDF \\
AZT
\end{bmatrix}$$
AZT / 3TC

## 3<sup>rd</sup> line ART

### 

## Assumes likely resistance to at least 2 prior agents


 Assumes failure to prior treatment with core of:

ATV/r or LPV/r or DTG

 For likely NRTI resistance, "flip" the backbone (or follow genotype)
 If failed on: Switch to:


ABC or TDF — AZT

## Initial Treatment Failure (go to Alt 1)




Any suspected hypersensitivity reaction = STOP the ART & DO NOT re-challenge

## NRTI & NNRTI Switches by adverse effects



## PI & INSTI Switches by adverse effects

**EFV** 



## Case

#### 32 year old female

- Weight loss and diarrhea for 6 months
- BMI now 18
- HIV diagnosed by rapid testing 1 month ago

How do you counsel?

What is your next step?

1 months later you see her in clinic

- Reports full adherence
- Diarrhea has stopped, weight is same as on start
- Notes that she has been feeling depressed

What do you review?

What are your next steps?

She returns for 2<sup>nd</sup> month review

- Nightmares developed
- She has stopped her ART for the past 2 weeks entirely

What is your next step?

You have switched your patient to a DTG-based regimen. Her 6 month viral load returns **detectable** but < 1,000.

What is your next step?

She discloses that her husband is a truck driver who travels a 3-day route each week. She has not disclosed to him for fear of his reaction and therefore does not take ART on days when he is home to avoid inadvertent disclosure.

How do you respond?

## Cases

55yoM with CKD recently started on DTG/ABC/3TC develops a cough and vomiting 2 weeks after starting.

• What is going on? Do you switch ART, and if so to what?

23yoF planning pregnancy soon sees you in clinic for new HIV diagnosis & ART start.

• How do you counsel her on ART options?

34yoF presents with suicidal ideation after starting ART recently. She does not know her meds and medical records are missing.

What ART might she be on, and what do you suggest?

## Cases

59yoM with HTN on NVP/TDF/3TC presents with 20lb weight loss and polyuria over 3 months.

What do you suspect? What studies do you order? What is your recommendation?

63yoF on NVP/AZT/3TC notes an increasingly protuberant abdomen and thinning facial soft tissue.

• What do you suspect? What is your recommendation?

33yoM on NVP/TDF/3TC has VL 2,350 after IAC and 3 months of good adherence.

• What is your recommendation?

43yoF on LPV/r/TDF/3TC with chronic diarrhea without weight loss for 3 months.

• What do you suspect? What is your recommendation?